Trial Profile
IAVI P001: A Phase I Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Safety and Immunogenicity of TBC-M4, a multigenic MVA HIV Vaccine vs ADVAX, a multigenic DNA HIV Vaccine followed by TBC-M4, a multigenic MVA HIV Vaccine
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs ADVAX (Primary) ; HIV vaccine-TBC M4 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India
- 27 Aug 2008 New trial record.